Drug intelligence / Profile preview

DWC202311

Development stage: Unknown
Lead developer: Daewoong Pharmaceutical
Modality: Small Molecules

Overview

DWC202311 is a small molecule drug developed by Daewoong Pharmaceutical. It has been studied in clinical trials as part of a bioequivalence and pharmacokinetic comparison with DWJ1558 and DWC202310 in healthy volunteers. The specific mechanism of action, therapeutic indication, and molecular target for DWC202311 have not been disclosed in publicly available sources as of June 2025. The drug appears to be at an early stage of development (Phase 1), with no evidence yet for its approval or use in any particular disease area[2][7].

Beyond the preview

Go deeper on DWC202311.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWC202311.

Explore the full profile